IP Library Granted Patent US 11,326,163
Granted Patent B2
US 11,326,163 · App. 16/633,909 · Granted May 10, 2022

Therapeutic agent for fibrosis

Inventors: Kazuhisa Nakao (Shimotsuga-gun, JP); Junichi Ishiyama (Tokyo, JP); Wataru Ichikawa (Tsukuba, JP); Atsushi Masui (Shimotsuga-gun, JP); Yunike Akasaka (Shimotsuga-gun, JP); Hidekazu Toyofuku (Kurume, JP); Aya Honda (Shimotsuga-gun, JP)
Assignee: KYORIN PHARMACEUTICAL CO., LTD.
C12N15/113A61K31/713A61K31/7105
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,326,163
App. No.
16/633,909
Granted
May 10, 2022
Kind
B2
Abstract

Disclosed is a phosphorylation inhibitor of SMAD2/3 protein or a therapeutic agent for fibrosis which contains as an active ingredient, a nucleic acid that suppresses NEK6 (NIMA-related serine/threonine kinase 6) gene expression.

Claims (10)

1. A method for treating fibrosis, comprising:

administering to a subject in need thereof a therapeutically-effective amount of a nucleic acid molecule having a guide strand and a passenger strand,

wherein the number of nucleotides in the guide strand and in the passenger strand are each 19- to 50-nt, and

wherein the guide strand includes a sequence suppressing expression, the sequence suppressing expression being complementary to NEK6 gene, to thereby suppress NEK6 gene expression.

2. The method according to claim 1 , wherein the nucleic acid molecule is a single-strand nucleic acid molecule forming a hairpin RNA structure.

3. The method according to claim 1 , wherein the guide strand forms an overhanging end.

4. The method according to claim 1 , wherein the fibrosis is pulmonary fibrosis, hepatic fibrosis, or kidney fibrosis.

5. The method according to claim 1 , wherein the number of nucleotides in the guide strand and in the passenger strand are each 19- to 30-nt.

6. The method according to claim 1 , wherein the number of nucleotides in the guide strand and in the passenger strand are each 19- to 25-nt.

7. The method according to claim 1 , wherein the number of nucleotides in the guide strand and in the passenger strand are each 19- to 23-nt.

Assignments (4)
CHANGE OF ADDRESS Recorded Dec 25, 2024
From: KYORIN PHARMACEUTICAL CO., LTD.
To: KYORIN PHARMACEUTICAL CO., LTD.
Reel/Frame 069784/0473 →
MERGER Recorded Nov 13, 2023
From: KYORIN PHARMACEUTICAL CO., LTD.
To: KYORIN HOLDINGS, INC.
Reel/Frame 065545/0869 →
CHANGE OF NAME Recorded Nov 13, 2023
From: KYORIN HOLDINGS, INC.
To: KYORIN PHARMACEUTICAL CO., LTD.
Reel/Frame 065545/0960 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2020
From: NAKAO, KAZUHISA; ISHIYAMA, JUNICHI; ICHIKAWA, WATARU; MASUI, ATSUSHI; AKASAKA, YUNIKE; TOYOFUKU, HIDEKAZU; HONDA, AYA
To: KYORIN PHARMACEUTICAL CO., LTD.
Reel/Frame 051612/0710 →
Priority Claims (1)
JP JP2017-146957 · Jul 28, 2017 · national
Continuity (1)
Related Publication 20210087556A1 · Mar 25, 2021